advertising
-
1.
Paavola M , Kannus P & Jarvinen T et al.: Achilles tendinopathy. J Bone Joint Surg Am 11: 2062, 2002.
-
2.
Roche AJ & Calder JD: Achilles tendinopathy: a review of the current concepts of treatment. Bone Joint J 10: 1299, 2013.
-
3.
Nelen G , Martens M & Burssens A: Surgical treatment of chronic Achilles tendinitis. Am J Sports Med 17: 754, 1989.
-
4.
Schepsis AA & Leach RE: Surgical management of Achilles tendinitis. Am J Sports Med 15: 308, 1987.
-
5.
Tallon C , Coleman BD & Khan KM. et al.: Outcome of surgery for chronic Achilles tendinopathy: a critical review. Am J Sports Med 29: 315, 2001.
-
6.
Paavola M , Orava S & Leppilahti J et al.: Chronic Achilles tendon overuse injury: complications after surgical treatment: an analysis of 432 consecutive patients. Am J Sports Med 28: 77, 2000.
-
7.
Paavola M , Kannus P & Orava S et al.: Surgical treatment for chronic Achilles tendinopathy: a prospective seven month follow up study. Br J Sports Med 36: 178, 2002.
-
8.
Kearney RS , Parsons N & Metcalfe D et al.: Injection therapies for Achilles tendinopathy. Cochrane Database Syst Rev 5: CD010960, 2015.
-
9.
Matteo BD , Filardo G & Kon E et al.: Platelet-rich plasma: evidence for the treatment of patellar and Achilles tendinopathy: a systematic review. Musculoskelet Surg 99: 1, 2015.
-
10.
Unlu MC , Kivrak A & Kayaalp ME et al.: Peritendinous injection of platelet-rich plasma to treat tendinopathy: a retrospective review. Acta Orthop Traumatol Turcica 51: 482, 2017.
-
11.
Zhang YJ , Xu SZ & Gu PC et al.: Is platelet-rich plasma injection effective for chronic Achilles tendinopathy? a meta-analysis. Clin Orthop Relat Res 8: 1633, 2018.
-
12.
Parolini O , Solomon A & Evangelista M et al.: “Human Term Placenta as a Therapeutic Agent: From the First Clinical Applications to Future Perspectives,” in Human Placenta: Structure and Development, ed by Berven, E p 1, Nova Science, Hauppauge, NY, 2010.
-
13.
Niknejad H , Peirovi H & Jorjani M et al.: Properties of the amniotic membrane for potential use in tissue engineering. Eur Cell Mater 15: 88, 2008.
-
14.
Zelen CM , Poka A & Andrews J: Prospective, randomized, blinded, comparative study of injectable micronized dehydrated amniotic/chorionic membrane allograft for plantar fasciitis: a feasibility study. Foot Ankle Int 34: 1332, 2013.
-
15.
Cazzell S , Stewart J & Agnew PS et al.: Randomized controlled trial of micronized dehydrated human amnion/chorion membrane (dHACM) Injection compared to placebo for the treatment of plantar fasciitis. Foot Ankle Int 39: 1151, 2018.
-
16.
Gellhorn AC & Han A: The use of dehydrated human amnion/chorion membrane allograft injection for the treatment of tendinopathy or arthritis: a case series involving 40 patients. PM R 9: 1236, 2017.
Micronized Dehydrated Human Amnion/Chorion Membrane Injection in the Treatment of Chronic Achilles Tendinitis
A Large Retrospective Case Series
Search for other papers by Jay E. Spector in
Current site
Google Scholar
PubMed
Search for other papers by Brandon Hubbs in
Current site
Google Scholar
PubMed
Search for other papers by Kimberly Kot in
Current site
Google Scholar
PubMed
Search for other papers by Niki Istwan in
Current site
Google Scholar
PubMed
Search for other papers by David Mason in
Current site
Google Scholar
PubMed
Background
Human amniotic membrane contains growth factors and cytokines that promote epithelial cell migration and proliferation, stimulate metabolic processes that lead to collagen synthesis, and attract fibroblasts, while also reducing pain and inflammation. Randomized studies have shown effectiveness of micronized dehydrated human amnion/chorion membrane (mdHACM) allograft injection in treatment of plantar fasciitis. We present our experience and short-term outcomes with using mdHACM injection as a treatment for Achilles tendinopathy.
Methods
Retrospective case series of patients with Achilles tendinopathy treated with mdHACM by a single physician. Participants had at least two follow-up visits within 45 days of mdHACM injection. Outcomes examined included change in reported level of pain during the 45-day observation period and treatment-associated adverse events.
Results
Follow-up data were available for 32 mdHACM-treated patients. At treatment initiation, 97% of patients reported severe (66%) or moderate (31%) pain. At the first follow-up visit (mean ± SD of 8.1 ± 2.7 days postinjection), 27 patients (84%) reported improvement in pain levels, although 37% of patients continued to report severe (6%) or moderate (31%) pain. At the second follow-up visit (mean ± SD of 23.1 ± 6.2 days postinjection), no patients reported severe pain and one reported moderate pain. Within 45 days of mdHACM injection, complete symptom resolution was reported by 66% of treated patients (n = 21), with the remaining 34% (n = 11) reporting symptom improvement but not complete resolution. Two patients reported calf or quadricep pain or tightness after injection.
Conclusions
In our experience, mdHACM injection reduced or eliminated pain in all 32 patients with follow-up data.
Atlanta Sports Podiatry, Atlanta, GA.
MiMedx Group Inc, Marietta, GA.
Istwan Consulting Services, Prescott, AZ.
advertising
